Poniard Pharmaceuticals, Inc.

IDAHO FALLS, Idaho and MADISON, Wis., Sept. 4, 2024 /PRNewswire/ -- International Isotopes, Inc. (INIS) and Phantech Medical (Phantech) have entered into a joint venture agreement to form PhanQual, which will design, manufacture, and distribute long-lived calibration and reference sources for pre-clinical applications. Phantech is a biomedical hardware company based in Madison, WI that serves the global medical imaging industry, with an emphasis on pre-clinical. Phantech is focused on serving the medical imaging community with innovative phantom technology to drive more accurate, streamlined and standardized quantitative and quality management procedures in medical imaging. INIS, through RadQual, a wholly owned subsidiary, has been a leader in sealed source calibration and reference sources since 2001. RadQual designs & develops, manufactures and globally distributes sealed calibration and reference sources for medical applications, laboratory equipment, industrial, and research and scientific applications. PhanQual will leverage INIS's and Phantech's technologies, facilities, experience, and global network to design, manufacture, and distribute sealed sources, including adapting Phantech's patented and cutting-edge fillable calibration source technology, into sealed source calibration devices to better serve the R&D and theranostics community. Additionally, RadQual will globally distribute Phantech's entire portfolio of fillable sources through RadQual's global network of distributors. "With nearly three decades in nuclear medicine, the International Isotopes Inc. team has shown their commitment to serving the medical imaging community and improving healthcare, which aligns with our mission. In that time, INIS has built an expert team and a vast global network to manufacture and distribute radioactive devices, which made it an easy decision for Phantech to partner with INIS. Our philosophies and motivations for progressing and improving the accuracy in nuclear medicine imaging and theranostics get us excited about what will come from this partnership," said Justin Jeffery, Co-Founder and Head of R&D of Phantech. Benjamin Cox, PhD, Co-Founder and Head of Hardware Design of Phantech added that "INIS's expansive portfolio of radioisotopes coupled with their eagerness to innovate made them a logical partner to create sealed sources based on our novel preclinical geometries. Together, we will increase the availability and accessibility of these calibration sources to customers around the world." Shahe Bagerdjian, President and CEO of International Isotopes added "The Phantech team have built a strong portfolio of next-generation fillable sources and their work and passion really caught our eye. Entering the pre-clinical space was the next step in making RadQual the global leader in all calibration and reference sources; it was only natural for us to partner with Phantech to launch the PhanQual series of nuclear medicine devices. We are well aligned with Justin and Ben on our goals to bring in additive manufacturing and artificial intelligence to create calibration devices which help enhance the work researchers are doing to save lives." To learn more about PhanQual, please visit or email [email protected] About Phantech Phantech, established in 2018, with headquarters in Madison, WI, USA, designs and manufacturers medical theranostic phantoms for PET, SPECT, CT, optical (FLI/BLI), MRI, radioluminescence, ultrasound, magnetic particle imaging, systemic targeted radionuclide therapy (TRT) and external beam radiation therapy (XRT). Recently, Phantech has partnered with Gremse-IT GmbH (Germany) to automate the analysis of Phantech's nuclear medicine phantoms, which includes the new PhanQual product line. About International Isotopes Inc. International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. INIS recently launched a manufacturing joint venture with Alpha Nuclides, to bring INIS and RadQual products into China via Radnostix China. International Isotopes Inc. Safe Harbor Statement Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at , including its Annual Report on Form 10-K for the year ended December 31, 2023. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. FOR MORE INFORMATION ABOUT INIS, CONTACT: David Drewitz Creative Options Communications Investor and Public Relations [email protected] Phone: 972-814-5723 FOR MORE INFORMATION ABOUT PHANTECH, CONTACT: Benjamin Cox Cofounder, Head of Hardware Design [email protected] SOURCE International Isotopes Inc.

IDAHO FALLS, Idaho and NINGBO, China, June 7, 2024 /PRNewswire/ -- International Isotopes, Inc. (INIS) and Alpha Nuclide Inc (AN) have entered into a Strategic Development and Distribution Agreement for the rights to manufacture and distribute INIS's Theranostics and nuclear Medicine Products in mainland China. Alpha Nuclide is a global leading supplier of alpha-particle emitting radionuclides and a radiopharmaceutical CRDMO. INIS is a global supplier of medical isotopes, radiopharmaceuticals, sealed source devices, and medical devices for radioisotopes. Alpha Nuclide currently operates from Hangzhou Bay district and is setting up a world-class facility with a 30 MeV proton and a 30 MeV alpha beam cyclotron for the production of alpha-emitter and positron-emitter radionuclides for theranostic applications, such as Astatine-211, Actinium-225, Zirconium-89, Copper-64 and Germanium-68, in Haiyan, Jiaxing, China; which is located just outside of Shanghai. The parties will begin with the distribution of INIS's RadQual™ calibration sources as phase I of the strategic alliance, with further planned milestones for the establishment of a joint venture to register INIS's Theranostics & Nuclear Medicine Products with the CFDA for local manufacturing and distribution. The parties envision commercializing INIS's radiopharmaceutical Iodine-131, radiochemical API, and theranostics API I-131 for 3rd party therapeutic applications in China. The parties intend to manufacture and distribute these the INIS products from AN's Jiaxing facility. The parties also intend to enter into a supply agreement for raw material isotopes to be supplied from Alpha Nuclide and used in INIS's manufacturing process. I-131 for Thyroid Disease diagnosis and radio-therapy in China represents the majority of all radioisotope uses in China. Currently, hospitals and pharmacies in China are primarily dependent on supply from Europe or the U.S., leading to issues with reliability of service and access to treatment. In June of 2021, the National Health Commission, Ministry of Science and Technology, and six other departments issued the Medium- and Long-term Development Plan for Medical Isotopes (2021-2035). The plan aims to improve the medical isotope industry and related industries to support the "Healthy China" initiative. It also aims to create a stable and independent medical isotope supply system. "Alpha Nuclide is delighted and excited to partner with INIS in a multifaceted collaboration, connecting the Chinese market with a US company, and vice versa. Our vision for growth in the radiopharmaceutical space is aligned as we focus on the supply of radionuclides and the logistics for manufacture and supply of radiopharmaceuticals. INIS is one of the biggest players in this space, and have a global reach in radiopharmacies and other radiopharmaceutical end users. AN's strategy is complimentary to INIS. This collaboration will be mutually beneficial and bring exciting growth for both parties" said Yutian Feng, Co-Founder and CEO of Alpha Nuclide Inc. "INIS is proud to partner with Alpha Nuclide to increase regional supply and expand access to radiopharmaceuticals in China. Alpha Nuclide has accomplished a lot in their early years. In my experience in operating the leading radiopharmacy network in China, I see Alpha Nuclide as the perfect multi-dimensional partner to team up with. For us at INIS, this is the next phase of our global growth strategy and we are excited to get the project going" said Shahe Bagerdjian, President and CEO of International Isotopes. About Alpha Nuclide Alpha Nuclide is a commercial supplier of medical radioisotopes such as astatine-211, actinium-225, germanium-68, lead-203, copper-64 and etc. Alpha Nuclide also provides contracted research services for the development of radiopharmaceuticals and manufacture services of radiopharmaceuticals to support clinical trials. Alpha Nuclide's headquarter is located in the Hangzhou Bay district in Ningbo, where a Level-2 RAM licensed lab is fully operational and equipped with radioactivity processing labs, radiochemistry labs, a cell culture facility and a small animal facility. Alpha Nuclide is also building a Level-1 RAM licensed facility in Haiyan, Jiaxing, where we plan to install 2 30-MeV cyclotrons along with GMP processing facility to supply medical radioisotopes and manufacture GMP grade radiopharmaceuticals. About International Isotopes Inc. International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. International Isotopes Inc. Safe Harbor Statement Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at , including its Annual Report on Form 10-K for the year ended December 31, 2023. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. FOR MORE INFORMATION ABOUT INIS, CONTACT: David Drewitz Creative Options Communications Investor and Public Relations [email protected] Phone: 972-814-5723 FOR MORE INFORMATION ABOUT ALPHA NUCLIDES, CONTACT: Weibin Zhuo VP & Co-founder +86 189 0220 7829 [email protected] SOURCE International Isotopes Inc.

SAN FRANCISCO--(BUSINESS WIRE)-- Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of a new independent director, Neela Patel, Ph.D., to the company's Board of Directors. Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals. “We are thrilled to welcome Neela as an independent Board member,” said Dr. Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “With over 25 years of leadership experience spanning drug discovery, development, strategic partnerships, and corporate development, she brings invaluable expertise to Infinimmune. Her proven track record of pipeline development and strategic collaborations will be invaluable as we continue to advance our programs and pursue new opportunities for growth.” “I am excited to join Infinimmune and contribute to its mission of identifying and developing truly human therapeutics to develop safer, more effective therapies for patients,” said Patel. “I look forward to contributing my expertise in deal-making and drug discovery to the long-term success of Infinimmune. The outstanding team and transformative platform technology position the company to build a remarkable pipeline.” Dr. Patel is a scientist and business development executive with more than 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation. She is currently Chief Business Officer at Bonum Therapeutics. Prior to Bonum, she was Chief Business Development Officer at Good Therapeutics, where she co-led the Roche transaction and spinout of Bonum. Previously, as Executive Director of Corporate Development at Seagen, she played an integral role in deal sourcing and execution to build the pipeline, including agreements with Pieris and FivePrime. Her sourcing and diligence at AbbVie resulted in more than 25 executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery with positions of increasing responsibility, advancing small molecules and biologics from target ID and validation through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience. Dr. Patel completed her postdoctoral training at the DNAX Research Institute after receiving her PhD in Molecular Biology from UCLA. She graduated Phi Beta Kappa from Stanford with a B.S. in Biology and a B.A. in Humanities with Honors. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.